Zum Hauptinhalt springen

Transcriptomics and network analysis highlight potential pathways in the pathogenesis of pterygium.

de Guimarães JA ; Hounpke, BW ; et al.
In: Scientific reports, Jg. 12 (2022-01-07), Heft 1, S. 286
Online academicJournal

Transcriptomics and network analysis highlight potential pathways in the pathogenesis of pterygium 

Pterygium is a common ocular surface condition frequently associated with irritative symptoms. The precise identity of its critical triggers as well as the hierarchical relationship between all the elements involved in the pathogenesis of this disease are not yet elucidated. Meta-analysis of gene expression studies represents a novel strategy capable of identifying key pathogenic mediators and therapeutic targets in complex diseases. Samples from nine patients were collected during surgery after photo documentation and clinical characterization of pterygia. Gene expression experiments were performed using Human Clariom D Assay gene chip. Differential gene expression analysis between active and atrophic pterygia was performed using limma package after adjusting variables by age. In addition, a meta-analysis was performed including recent gene expression studies available at the Gene Expression Omnibus public repository. Two databases including samples from adults with pterygium and controls fulfilled our inclusion criteria. Meta-analysis was performed using the Rank Production algorithm of the RankProd package. Gene set analysis was performed using ClueGO and the transcription factor regulatory network prediction was performed using appropriate bioinformatics tools. Finally, miRNA-mRNA regulatory network was reconstructed using up-regulated genes identified in the gene set analysis from the meta-analysis and their interacting miRNAs from the Brazilian cohort expression data. The meta-analysis identified 154 up-regulated and 58 down-regulated genes. A gene set analysis with the top up-regulated genes evidenced an overrepresentation of pathways associated with remodeling of extracellular matrix. Other pathways represented in the network included formation of cornified envelopes and unsaturated fatty acid metabolic processes. The miRNA-mRNA target prediction network, also reconstructed based on the set of up-regulated genes presented in the gene ontology and biological pathways network, showed that 17 target genes were negatively correlated with their interacting miRNAs from the Brazilian cohort expression data. Once again, the main identified cluster involved extracellular matrix remodeling mechanisms, while the second cluster involved formation of cornified envelope, establishment of skin barrier and unsaturated fatty acid metabolic process. Differential expression comparing active pterygium with atrophic pterygium using data generated from the Brazilian cohort identified differentially expressed genes between the two forms of presentation of this condition. Our results reveal differentially expressed genes not only in pterygium, but also in active pterygium when compared to the atrophic ones. New insights in relation to pterygium's pathophysiology are suggested.

These authors contributed equally: Juliana Albano de Guimarães and Bidossessi Wilfried Hounpke.

Introduction

Pterygium is a common disease of the ocular surface, consisting of a fibrovascular tissue that arises from the conjunctiva and extends to the cornea. It is related to irritative symptoms, poor aesthetics, astigmatism and, sometimes, worsening visual acuity, being a condition frequently associated with decreased quality of life. The prevalence of pterygium varies according to the region studied, being higher in tropical regions, where the prevalence is approximately 22%, and lower in countries outside these areas, where it is close to 2%[1],[2]. In Brazil, the reported rate of pterygium in a city of the Southwest region was 8.12%[3], while in indigenous populations of the Brazilian Amazon rainforest, the prevalence varied from 18.4 to 36.6%[4]. Several risk factors for pterygium have been listed, although the most frequent ones are exposure to ultraviolet radiation, chronic irritation and inflammation[5]–[7]. Surgery is considered for symptomatic and cosmetic improvement, but recurrence can happen in 0 to 88% of the cases, depending on the surgical technique employed[8]. The development of the pterygium has some similarities with tumor growth, such as fibrovascular proliferation, corneal invasion and high recurrence rate after surgical excision[9]. Among the mechanisms and structures involved, it is known that the proliferation and degeneration of collagen fibers, especially type I collagen, plays an important role in the development of the pterygium[10]. Several studies also demonstrate the role of anti-apoptotic mechanisms, modulation of extracellular matrix under ultraviolet radiation exposure, angiogenesis, inflammation and hereditary factors in the pathogenesis of pterygium[11]–[13]. However, the exact pathogenesis is not yet fully understood and the precise identity of the critical triggers as well as the hierarchical relationship between all the elements involved in the pathogenesis of this disease are yet to be described.

In view of the controversies on the multiple mechanisms of pterygium formation, studies were carried out using high-throughput genomic technologies, such as microarrays, to attempt to elucidate mRNA expression patterns that could underlie specific molecular events of interest in its pathogenesis[14],[15]. Also, several other studies analyzed non-coding RNA expression, evidencing upregulated and downregulated miRNAs and lncRNAs that could be involved in pterygium pathogenesis[12],[16]–[25]. Microarray-based studies generate large databases of raw gene expression that are deposited in data repositories for public reuse. In turn, meta-analysis of these data may enhance results and generate new biological insights regarding some conditions in comparison with individual studies, once it reduces study biases, increases statistical power and obtains a more accurate evaluation of differentially expressed genes (DEGs).

Over the past decade, the availability of large public genomic datasets and robust bioinformatics tools enabled the development of new data mining approaches in biomedical research[26]. Consequently, the field of integrative analysis of high throughput gene expression datasets has grown exponentially, leading to the development of tools and guidance for conducting a meta-analysis of gene expression[14],[27],[28]. Meta-analysis of transcriptomic datasets deposited in public repositories represents an attractive strategy capable of identifying key pathogenic mediators and therapeutic targets in complex diseases[14],[29],[30]. By combining multiple study datasets, this strategy has the potential to increase the statistical power and to generate new biological insights that could not be accessed from original studies[14]. Moreover, several bioinformatics tools of curated biological databases[31]–[33] have been recently developed, making even easier the interpretation of relevant differentially expressed (DE) genes sets identified from meta-analysis and the prediction of associated pathways and regulatory networks[29],[31],[32],[34]. In this context, a well conducted meta-analysis has the potential to contribute to the generation of new hypothesis about the pathogenic mechanisms of complex diseases.

The aims of this study were to evaluate gene expression in pterygium samples, perform a meta-analysis with two databases available at the Gene Expression Omnibus public repository and then, correlate the findings through a miRNA-mRNA regulatory network.

Methods

Microarray data analysis of the Brazilian cohort

Sample collection

The present study was carried out with the approval of the Research Ethics Committee of the University of Campinas (UNICAMP) and was conducted in accordance with the tenets of the Declaration of Helsinki and current legislation on clinical research. Written informed consent was obtained from all subjects after explanation of the procedures and study requirements.

Participants were selected by convenience, at the Ocular Surface outpatient clinic of the Hospital of University of Campinas. Participants that presented nasal pterygia, not previously operated, and wanted surgery were included. Individuals with conjunctival surface diseases such as previous chemical burns, pemphigoid and cicatricial diseases, or suspected ocular surface neoplasia were excluded.

The pterygium was classified according to the fibrovascular tissue extension towards the cornea (grade 1 when the lesion reaches the limbus, grade 2 when it covers the cornea at about 2 mm, grade 3 when it reaches the pupil margin and grade 4 when it exceeds the pupil) and according to its biomicroscopic aspect (atrophic when the visualization of structures immediately below is possible, or active when fibrovascular tissue prevents proper visualization of underneath structures). The latter classification is based on the classification proposed by Tan et al., in which the pterygia are divided according to tissue translucency. Grade T1 (atrophic) denotes a pterygium in which episcleral vessels underlying the body of the pterygium are unobscured and clearly distinguished. Grade T3 (active or fleshy) denotes a thick pterygium in which episcleral vessels underlying the body of the pterygium are totally obscured. All other pterygia that do not fall into these 2 categories are classified as Grade 2 (intermediate). An increased fleshiness or thickness of the fibrovascular component of the pterygium is believed to be associated with recurrence after excision[35].

Participants underwent pterygium excision followed by an upper bulbar conjunctival free autograft placed over the site of the original lesion. All pterygia specimens were nasally located. The entire pterygium tissue was collected, and the samples were immediately stored in RNAlater stabilization solution (Invitrogen) until RNA extraction.

Microarray assay

Tissue samples were transferred to liquid nitrogen and ground into powder. Total RNA extraction was performed using TRIzol Reagent (Invitrogen) and purified with RNeasy RNA extraction kit (Qiagen) according to the manufacturer's protocol. RNA concentration and purity were assessed through NanoDrop 2000 spectrophotometer (Thermo Scientific) whereas RNA integrity was measured in the Bioanalyzer 2100 System (Agilent Technologies). Samples with an RNA integrity number ≥ 7 were subjected to microarray analysis.

Fifty nanograms of total RNA were used to generate ss-cDNA, which was hybridized on Human Clariom D Assay gene chip (Affymetrix). This array interrogates more than 540,000 human transcripts. Sample labeling, hybridization, washing and scanning were performed according to manufacturer's protocols at Molecular Core Facility (São Paulo, SP, Brazil).

Microarray data normalization and probe sets annotation

The normalization of the transcriptomic data of 9 samples from our cohort was performed by SST-RMA summarization to generate gene level expression signals using Transcriptome Analysis Console (TAC 4.0, Applied Biosystems) software after the evaluation of quality control metrics. Affymetrix probes were annotated to human genome hg38 version using TAC software and the Clariom D annotation file Clariom_D_Human.r1.na36.hg38.a1.transcript.csv. Probes mapped to more than one gene were removed and logarithm transformed expression data was exported for further analysis[33],[36].

This normalized expression data of the Brazilian cohort was later used for extracting the expression intensity of miRNAs and their respective targets to reconstruct the miRNA-mRNA regulatory network, that was based in data from the meta-analysis (described later).

Evaluation of DE genes comparing active vs atrophic pterygium

To identify the divergent gene expression pattern between active and atrophic pterygium, a differential gene expression analysis was performed using a linear model fitted in limma package[37] after adjusting variables by age. We also applied the Empirical Bayes framework to estimate the more precise expression of each gene to discriminate DE genes. DE genes were identified based on the adjusted p valor < 0.05 and filtered with the fold change values. To evaluate the discriminatory capacity of each DE gene, we computed the area under (AUC) the ROC curve using pROC package[38].

Meta-analysis of gene expression studies

Pre-processing

Microarray raw data were pre-processed using the Robust Multichip Average (RMA) method[39] implemented in the oligo package[40] as previously described[29]. Briefly, RMA algorithm performs background subtraction which intends to minimize the effects of the noises inherent to microarray technology. Quantile normalization and median-polish steps are then applied to mitigate the effects of technical variables through the estimation of a common intensity distribution across samples. Probes are summarized into a single probe set corresponding to a single gene and expression is then transformed in log-scale. Probe sets were annotated using biomaRt packages[41].

Identification of eligible datasets

Gene expression datasets from microarray studies including human patients that underwent pterygium excision were searched in the Gene Expression Omnibus (GEO) public repository, by December 2020. Search was conducted using the term "pterygium". Datasets were only included if the studies analyze both affected patients and healthy tissues. All included datasets were from studies published in peer-reviewed journals. In addition, studies were excluded if samples were submitted to cell culture.

Meta-analysis of gene expression

The meta-analysis was performed with RankProd package[42] using Rank product algorithm. A non-parametric method is applied to detect genes consistently ranked as DE by comparing patients to healthy controls in each dataset. Thus, this method overcomes the heterogeneity among multiple datasets by transforming the actual expression values into ranks[42] and computes the p value and the false discovery rate (FDR) of each DE gene. The gene list was further filtered to include only genes that were up- or down-regulated in the same direction in both studies based on a false discovery rate (FDR) < 0.05 as previously described[29]. Heatmap visualization of the subset of 30 top DE genes was performed using the heatmap Bioconductor package[43] after expression recalibration using a list of human housekeeping genes derived from the HRT Atlas database[44].

Functional gene set analysis

To facilitate the interpretation of the biological significance of the up-regulated genes identified by the meta-analysis, a functional gene set analysis (GSA) was performed using ClueGO[45]. ClueGO is a plug-in of Cytoscape[36], which predicts the functional gene ontology terms or biological pathways and organizes them in functionally grouped networks, highlighting the biological relationship between them. ClueGO's fusion criterion was applied to reduce the redundancy of the terms that have similar associated gene sets. In order to filter the most important terms and pathways, we used two-sided hyper-geometric distribution tests and terms at a significant level Bonferroni adjusted p-value of ≤ 0.05.

Functional analysis of down-regulated genes

To gain more insights into the biological processes associated with the down-regulated signature, these genes were used for an additional functional analysis based on the Functional Analysis of Individual Microarray/RNAseq Expression (FAIME) algorithm implemented in seq2pathway package[34]. Briefly, FAIME determines at a single sample level the cumulative quantitative effects of genes inside the differentiated Gene Ontology terms and biological processes. A FAIME score is then computed based on the gene expression pattern of each sample for the predicted terms or biological processes. Receiver operating characteristic (ROC) curve was computed to evaluate the discriminatory capacity of each of these enriched terms for a binary classification. In this analysis, the binary classification was pterygium vs control, across FAIME scores computed for each pathway. We computed the area under (AUC) the ROC curve using pROC R package[38]. Finally, we selected the enriched terms with AUC equal or more than 0.7 and network visualization was performed using cytoscape software[36].

Prediction of miRNA-mRNA regulatory network

The list of targeted genes included in this analysis was derived from the functional gene set analysis performed with the up-regulated genes identified by the meta-analysis. Briefly, we extracted the list of genes associated with the functional gene ontology terms and biological pathways predicted by ClueGO. The list of conserved miRNAs predicted to target these genes was identified in TargetScanHuman[33]. To reconstruct the miRNA-mRNA regulatory network, the expression intensity of each miRNA and their respective targets was extracted from the normalized expression data of the Brazilian cohort of pterygium. Pairwise correlation was computed between miRNA and their targets. miRNAs that have a negative correlation (R equal or less than -0.5) with at least one target were selected for the network reconstruction. Network visualization was performed in Cytoscape[36] software considering miRNA and mRNA as source and target nodes respectively.

Results

Collected data

Nine participants were included, being 6 males (aged 29–70 years old) and 3 females (aged 27–48 years old). The pterygia were classified as grade 1 in 1 case, grade 2 in 4 cases, grade 3 in 3 cases and grade 4 in 1 case. According to their biomicroscopic aspect, there were 2 atrophic and 7 active pterygia. Demographic information of the participants is presented in Table 1.

Table 1 Demographic information of the participants.

Participants

Age

Gender

Grade

Biomicroscopic aspect

1

45

Female

2

Active

2

53

Male

2

Atrophic

3

34

Male

1

Active

4

70

Male

3

Atrophic

5

27

Female

2

Active

6

48

Female

3

Active

7

35

Male

2

Active

8

51

Male

4

Active

9

29

Male

3

Active

Evaluation of genes that are divergently expressed between fleshy and atrophic pterygium

We evaluated the differential expression comparing active pterygium with atrophic pterygium using data generated from the Brazilian cohort. This analysis identified 219 up-regulated and 92 down-regulated genes. The pattern of gene expression generated with top 30 DE genes is presented as heatmap in Fig. 1. The top 10 up- and down-regulated genes and their main biological processes are presented in Table 2.

Graph: Figure 1 Heatmap plot of top 30 differentially expressed genes from the comparison of active pterygium with atrophic pterygium filtered by the fold change. The pattern of gene expression shows two different unsupervised clusters indicating a divergent expression pattern between these two clinical aspects. High expression is indicated in red and low expression is indicated in blue.

Table 2 List of top 10 up- and down-regulated genes in active vs atrophic pterygium and their associated biological processes.

DE

Fold change

p value

AUC

Main biological process

Up-regulated

CXCL9

126.36

0.0003

0.86

Immune and inflammatory response

TYRP1

8.76

0.0065

0.86

Aldosterone synthesis and secretion

SERPINB5

7.29

0.0002

1.00

Angiogenesis

BMP4

7.04

0.0006

1.00

Degradation of the extracellular matrix

TYR

6.95

0.0006

1.00

(S)-reticuline biosynthesis and Tyrosine metabolism

PIM1

6.78

0.0075

0.93

Cell growth. differentiation and apoptosis

VSNL1

6.28

0.0016

1.00

Modulation of intracellular signaling pathways

MLANA

5.64

0.0007

1.00

NF-kappaB Signaling

PLA2G2D

5.44

0.0043

0.71

Targets extracellular lipids; anti-inflammatory and immunosuppressive functions

DSG1

5.35

0.0002

1.00

Keratinization

Down-regulated

CIART

0.03

0.0032

1.00

Circadian rhythm

AQP9

0.16

0.0001

1.00

Transporter activity and glycerol channel activity

LINC01001

0.17

0.0091

1.00

*

mir1279

0.18

0.0005

1.00

#

CXCL6

0.18

0.0027

1.00

Chemotactic and angiogenic properties

TEF

0.19

0.0083

1.00

Circadian rhythm

TREM1

0.21

0.0024

1.00

Cell surface interactions at the vascular wall

COL6A3

0.22

0.0025

1.00

Integrin Pathway and Collagen chain trimerization

mir604

0.23

0.0009

1.00

#

NEURL4

0.23

0.0004

1.00

Ubiquitination and proteasome-dependent degradation

*Long non coding RNA; # miRNA.

Studies included in the meta-analysis

Three studies (GSE2513, GSE51995 and GSE83627) fulfilled the inclusion and exclusion criteria described in methods section of which two datasets (GSE51995 and GSE83627) were identified as duplicated datasets by PCA analysis (Fig. 2; 8 samples in each dataset). An exploratory analysis also confirms the presence of 8 duplicates based on the comparison of the normalized expression of that datasets. Therefore, GSE83627 was removed from the meta-analysis. The studies of the final analysis include data from 8 conjunctiva samples and 12 pterygium samples.

Graph: Figure 2 Gene expression pattern of conjunctiva and pterygium from the meta-analysis. The heatmap was constructed using the top 30 differentially expressed genes (15 up- and 15 down-regulated). The dendrogram indicates two clusters stratified using hierarchical clustering. Expression pattern was rescaled using a list of human housekeeping genes from HRT Atlas database[44]. High expression is indicated in red and low expression is indicated in blue.

Differential expression of pterygium

The meta-analysis identified 154 up-regulated and 58 down-regulated genes (Table 3). The top 10 up- and down-regulated genes are presented in Table 3. A heat map visualization of the expression pattern of the top 30 DE genes identified from the meta-analysis showed a stratification of conjunctiva and pterygium samples in two different clusters (Fig. 2).

Table 3 Top differentially expressed genes identified in the meta-analysis.

Genes

Fold-change in individual studies (log2 FC)

Meta-analysis results

GSE2513

GSE51995

Ave log2(FC)

FC

FDR

Up-regulated genes

SPRR3

2.16

3.78

2.97

7.85

< 0.0001

SPRR1B

1.91

3.23

2.57

5.94

< 0.0001

OLFM4

0.23

4.61

2.42

5.35

< 0.0001

KERA

0.53

4.02

2.28

4.85

< 0.0001

TFF1

2.49

1.66

2.07

4.21

< 0.0001

ASPN

1.39

2.37

1.88

3.67

< 0.0001

GJA1

1.04

2.58

1.81

3.51

< 0.0001

KRT3

0.09

3.51

1.80

3.49

< 0.0001

S100P

1.15

2.44

1.79

3.47

< 0.0001

KRT16

0.74

2.76

1.75

3.36

< 0.0001

Down-regulated genes

FOS

− 3.84

− 3.21

− 3.53

0.09

< 0.0001

FOSB

− 2.39

− 2.73

− 2.56

0.17

< 0.0001

WIF1

− 0.49

− 4.06

− 2.28

0.21

< 0.0001

NR4A2

− 2.21

− 1.68

− 1.94

0.26

< 0.0001

DUSP1

− 1.82

− 1.85

− 1.84

0.28

< 0.0001

TFPI2

− 0.84

− 2.47

− 1.65

0.32

< 0.0001

TNNI2

− 1.46

− 1.74

− 1.60

0.33

< 0.0001

CYP26A1

− 1.21

− 1.58

− 1.39

0.38

< 0.0001

IGFBP3

− 1.21

− 1.43

− 1.32

0.40

< 0.0001

IER2

− 1.12

− 1.47

− 1.29

0.41

< 0.0001

BTG2

− 1.17

− 1.38

− 1.28

0.41

< 0.0001

Genes were ranked according to the fold change. FC: Fold-change; Ave log2(FC): Base 2 logarithmic scale of average FC; FDR: False Discovery Rate. Ave log2(FC) is expressed as arithmetric mean log2(FC) across studies.

Pterygium up-regulated gene signature highlights a prominent role of extracellular matrix deg...

To gain further insights into the biological mechanisms associated with the expression pattern observed in the meta-analysis, a gene set analysis was performed with ClueGO using the full list of the up-regulated genes. This tool clusters biological pathways and gene ontology terms that participate in the same biological function, thereby showing the top significant non-redundant biological pathways and gene ontology terms (Fig. 3). Pathways associated with the remodeling of extracellular matrix were overrepresented in this gene set analysis. The following groups were also represented in the network: serine-type endopeptidase activity, formation of cornified envelope, estrogen signaling pathway, unsaturated fatty acid metabolic process, regulation of sensory perception of pain, positive regulation of calcium ion transport into cytosol and regulation of biomineral tissue development. ClueGO also enables the visualization of gene interactions between different gene ontology and biological pathways. Based on network connectivity, MMP2, FN1, COL11A1, LAMB3, THBS2 and YAP1 were predicted as hub genes and might play prominent role in the organization of this network. Interestingly, these genes show a tight relationship between extracellular matrix remodeling terms and other pathways and ontology terms (Fig. 3).

Graph: Figure 3 Functional analysis of up and down regulated genes in pterygium. The main pathways that are altered in patients with pterygium are indicated by colored nodes. GSA terms are interconnected with their shared genes. Close related terms are indicated by more than one color. GSA: Gene Set Analysis.

Prediction of the interaction networks of the DE genes and miRNAs in pterygium

To further explore the mechanism of regulation underlying the biological processes identified in the meta-analysis, we reconstructed the miRNA-mRNA target prediction network based on the set of up-regulated genes presented in the gene ontology and biological pathways network (Fig. 3). This strategy allows the identification of 17 target genes negatively correlated with their interacting miRNAs from the Brazilian cohort expression data (Fig. 4). Based on network connectivity analysis we identified two main clusters (Fig. 4A,B). Once again, the first cluster is associated with 4 enriched GSA terms involving extracellular matrix remodeling mechanisms (Fig. 4A). The second cluster involves three biological processes: (1) formation of the cornified envelope, (2) establishment of skin barrier and (3) unsaturated fatty acid metabolic process (Fig. 4B).

Graph: Figure 4 miRNA-mRNA targeting networks generated from the Brazilian cohort. miRNA-mRNA interaction was predicted using TargetScanHuman database. Pairwise correlation was computed between miRNA expression and the expression of the set of up-regulated genes presented in the gene ontology network generated in Fig. 2A. Only miRNA and genes which have negative correlation (less than − 0.50) were included. Regulatory networks associated with extracellular matrix remodeling are clustered (A). The second cluster (B) involves 3 different terms including the formation of the cornified envelope, the establishment of skin barrier and unsaturated fatty acid metabolic process. Genes are represented in grey dots and dot size is proportional to the level of expression; miRNA are represented in blue and edges are labeled with the correlation level between miRNA and genes.

Down-regulated genes in the pterygium meta-analysis are associated with metabolic and regulat...

In order to study the mechanisms underlying the down-regulated pattern observed in the meta-analysis, we next performed a functional analysis based on FAIME algorithm that attributes at a single sample level a score to each predicted term or biological process. This analysis shows mainly GSA terms associated with metabolic and regulation pathways (Fig. 5) ranked by their discriminatory capacity to classify pterygium and control in different clusters (AUC equal or more than 0.7). Gene interactions between different gene ontology and biological pathways are shown in Fig. 5.

Graph: Figure 5 Functional analysis of the down-regulated genes identified in the meta-analysis based on FAIME algorithm. Main down-regulated pathways are indicated by colored nodes. Pathways were selected based on the FAIME scores computed using the expression of down-regulated genes (grey dots). AUC was used to evaluate the discriminatory capacity of each enriched term for a binary classification (pterygium vs. control). FAIME: Functional Analysis of Individual Microarray/RNAseq Expression; AUC: Area Under the curve.

Discussion

Despite being a common disease of the ocular surface, the pterygium exact etiopathogenesis is not yet fully understood. For this reason, a meta-analysis of transcriptomic datasets deposited in public repositories was performed in order to generate new biological insights about its pathogenic mechanisms. Furthermore, gene expression data was obtained from 9 Brazilian patients and later correlated with data from the meta-analysis.

In the Brazilian cohort, 66.7% of the patients were males, 44.4% had pterygium grade 2 and 77.8% had active pterygium. Demographic and epidemiological characteristics of this cohort are in accordance with previously described features of patients with pterygium in our region, as described by Artioli-Schelini et al., that found that most of the patients had active and grade 2 pterygia[3].

In our meta-analysis, we found 212 DEGs, being 154 up-regulated and 58 down-regulated genes. Amongst the top up-regulated genes, SPRR3, SPRR1B, OLFM4, KERA, TFF1, ASPN, GJA1, KRT3, S100P and KRT16 were the most significantly differentially expressed genes. On the other side, amongst the top down-regulated genes, FOS, FOSB, WIF1, NR4A2, DUSP1, TFPI2, TNNI2, CYP26A1, IGFBP3, IER2 and BTG2 were the most significantly differentially expressed ones. As in previous studies, we found that genes associated with wound healing response and extracellular matrix were the most predominantly overexpressed[46],[47]. SPRR3 and SPRR1B encode envelope proteins of keratinocytes, being part of the cornification process that culminates with the formation of a keratinized cell layer[46],[47]. In the conjunctiva, this occurs in response to desiccating stress, which is in accordance with known risk factors of pterygium, such as exposure to wind and high temperatures. KERA encodes a keratan sulfate proteoglycan that is involved in corneal transparency and its up-regulation probably leads to extracellular matrix changes. TFF1 is a gene that encodes small protease-resistant peptides, which are secreted by goblet cells in the conjunctiva and are involved in triggering wound-healing responses[48]. ASPN encodes a protein that is member of the small leucine-rich proteoglycan family, also being part of extracellular matrix. KRT3 and KRT16 encode keratin 3 and 16, respectively, which are protein members of the keratin family, associated with epithelial cell differentiation and cornification. S100 calcium binding protein C is involved in regulation of cell cycle progression, differentiation and also wound healing mechanisms, possibly having a role in the pathogenesis of pterygium through epithelial wound repair and response to stress[49]. TFPI2 encodes an inhibitory protein that inhibits plasmin, trypsin and other serine proteases, possibly playing a role in pterygium pathogenesis once it is involved in extracellular matrix modulation.

A meta-analysis performed by Xu and colleagues, based on three datasets (GSE2513, GSE51995 and GSE83627) available at the Gene Expression Omnibus public repository, disclosed upregulation of other genes in addition to the ones found in our meta-analysis, including FN1, a key molecule in the extracellular matrix, and PI3, involved in apoptosis, focal adhesion and extracellular matrix-receptor interaction[47]. In a study using gene microarray performed by Tong and colleagues, several pathways were also significantly affected in pterygium in comparison with uninvolved conjunctiva. Gene expression was predominantly of wound healing pattern, with upregulated genes encoding for extracellular matrix (ECM), structural and adhesion molecules, including fibronectin (FN1), CEACAM5 (CEA), CD24, SPARC, MSMB and TFF1[46]. In addition, Chen and colleagues performed RNA sequencing experiments on clinical pterygium tissues and normal conjunctival tissues and identified 200 upregulated DGEs and 139 downregulated DGEs. The upregulated genes were mainly associated with ECM and with cell adhesion and migration and included: FN1; ECM1, which encodes extracellular matrix protein 1; IQGAP2, associated with cell adhesion and cytoskeletal organization; GADD34, a growth cycle protein that is induced by cell stress; and CXCL12, an angiogenic chemokine[50]. Biological pathways overrepresented in the gene set analysis were highly related to remodeling of extracellular matrix, including its organization, degradation, associated proteoglicans and regulation of biomineral tissue development. It was evidenced not only in the network of up-regulated genes, but also in the correlation between this gene set with the miRNA expression obtained from the Brazilian cohort. Other pathways also represented in the network and in the correlation with miRNA expression included formation of cornified envelope, establishment of skin barrier and unsaturated fatty acid metabolic process, which are associated with wound healing response.

Amongst the genes correlated with miRNA expression from the Brazilian cohort, GJA1 encodes a protein called connexin 43, a component of gap junctions, COL6A3 encodes one of the chains of type VI collagen, a component of connective tissues, and THBS4 and THBS2 encode for members of the thrombospondin family, which are adhesive glycoproteins that mediate cell-to-cell and cell-to-matrix interactions. YAP1 is a gene known to play a role in the development and progression of multiple cancers as a transcriptional regulator of a signaling pathway. LOXL1 encodes a protein essential to the biogenesis of connective tissue, while LHFPL2 is a member of the superfamily of tetraspan transmembrane protein encoding genes.

Also, regarding the genes correlated with miRNA expression obtained from the Brazilian cohort, pathways involved with unsaturated fatty acid metabolic processes were found to be differentially expressed in pterygium. This supports other studies findings in which pterygium fibroblasts were found to have an increased activity of intracellular cholesterol metabolism and high expression of LDL receptors[51]–[53]. ALOX15B encodes a protein involved in the production of fatty acid hydroperoxides and FA2H, a protein that catalyzes the synthesis of a subset of sphingolipids. ABCC1 is involved in the transport across extra and intra-cellular membranes and UGCG, in the biosynthesis of glycosphingolipids, which are membrane components. PLA2G4A encodes a cytosolic phospholipase A2, an enzyme that catalyzes the hydrolysis of membrane phospholipids to release arachidonic acid. SCD encodes an enzyme involved in fatty acid biosynthesis, primarily the synthesis of oleic acid.

Also reinforcing previous studies findings, increased cellular proliferation and reduced apoptosis appear to be involved in pterygium development[47], highlighting similarities between pterygium and neoplasia. Clinical evidence of tumoral behavior include fibrovascular proliferation, corneal invasion, and high recurrence rate after surgical excision. The reduced recurrence rate of pterygia with the application of mitomycin-C, 5-fluorouracil or cyclosporine during or after surgery supports this finding, as does the fact that the main risk factor for pterygium formation is UV light exposure, equivalently to the most common skin tumors[54].

OLFM4 consists of an antiapoptotic factor that promotes tumor growth and also an extracellular matrix glycoprotein that facilitates cell adhesion. In pterygium's pathogenesis, it could be associated an uncontrolled tissue growth. GJA1, a member of the connexin gene family, encodes the major protein of gap junctions and is related to cell signaling, apoptotic processes and chronic inflammatory processes. The FOS gene family consists of 4 members, which are FOS, FOSB, FOSL1 and FOSL2. The proteins encoded by these genes are leucine zipper proteins involved in regulation of cell proliferation, differentiation and transformation. In addition, these proteins play a role in cellular response to reactive oxygen species and in inflammatory response[46]. WIF1 consists of a tumor suppressor gene that is epigenetically silenced in various cancers. NR4A2 encodes a nuclear receptor of the steroid-thyroid hormone-retinoid receptor family and may be involved in pterygium once it is associated with cellular response to oxidative stress and regulation of apoptotic signaling pathway. DUSP1 encodes a protein that plays an important role in the cellular response to environmental stress and in the negative regulation of cellular proliferation. TNNI2 encodes a component of the troponin complex, present in corneal epithelium, acting as an inhibitor of angiogenesis and tumor suppressor. CYP26A1 encodes a member of the cytochrome P450 superfamily of enzymes, involved with regulation of retinoic acid receptor pathway and response to vitamin A. IGFBP3, one of the insulin-like growth factor binding proteins, is involved in apoptotic processes and regulation of cell population proliferation. IER2 is an immediate early gene involved in cell motility and response to fibroblast growth factor. Lastly, the protein encoded by BTG2 appears to have antiproliferative properties, being associated with DNA damage response and repair and having a function of negatively regulating the mitotic cell cycle.

In Tong and colleagues' study, genes encoding for apoptosis (TGM2, IGFBP3 and DUSP1) and stress-inducible transcription regulator genes (ATF3, BTG2, EGR1, ERG2, FOS, JUN, NR4A1 and NR4A2) were down-regulated in pterygium, reinforcing the over-proliferative tendency in pterygium[46]. Downregulated genes in Chen and colleagues' study, in its turn, included LCN1, a member of the lipocalin family, LTF, a component of the innate immune system, and SCGB2A1[50]. Biological functions found to be down-regulated in pterygium in comparison with normal conjunctiva included regulation of cell differentiation and cellular component organization, oxidation–reduction processes and negative regulation of cell death. This reinforces the similarities between pterygium and tumor growth[9], although differences still exist. Amongst the differences between the two conditions, the fact that extracellular matrix remodeling is the main mechanism found in pterygium's pathogenesis, and not cellular proliferation, is one of them. The main histologic findings in pterygium's specimens include squamous metaplasia, hyperplasia of goblet cells, underlying disrupted Bowman's layer, stromal fibroblasts and vessels, altered extracellular matrix with accumulation of collagen and elastin fibers, and inflammatory infiltration[55]. As shown in previous studies, histopathology only rarely discloses neoplasia or moderate/severe atypia in excised pterygia[55]–[57].

Finally, we could determine differences in gene expression between atrophic and active pterygium, leading to the conclusion that distinct biological pathways may be differently combined in terms of up and down-regulation to result in certain phenotypic characteristics of pterygium. In active pterygium, genes involved with immune and inflammatory response (CXCL9 and PLA2G2D), angiogenesis (SERPINB5 and BM4), keratinization (DSG1), response to UV light (TYR) and negative regulation of apoptotic process (PIM1) are up regulated in relation to atrophic pterygium. On the other side, genes involved with negative regulation of transcription (CIART), response to osmotic stress (AQP9), chemotaxis (CXCL6), intracellular signal transduction (TREM1), extracellular matrix organization (COL6A3) and protein ubiquitination (NEURL4) are down regulated in relation to atrophic pterygium.

Limitations of the study included the Brazilian sample size, which was not large, in addition to an absence of healthy conjunctival samples to compare with pterygium samples. Consequently, these samples were not included in the analysis of up and down regulated genes of the main meta-analysis, which was based on already available datasets. Brazilian data was used for the reconstruction of the miRNA-mRNA regulatory network and for a transcriptomic analysis in which active and atrophic pterygia were compared. Even though the sample size of this analysis was limited, the top ranked genes made it possible to stratify active and atrophic pterygium in different clusters using unsupervised clustering method as shown in Fig. 1.

In conclusion, reinforcing previous studies, we identified crucial pathways in the pathophysiology of pterygium, with the main ones being related to extracellular matrix remodeling and dysregulated wound healing response. Furthermore, different pathways involved in the pathogenesis of pterygium were evidenced to be related to different phenotypic characteristics of this condition, which may also provide some clarity in our understanding of this condition's pathophysiology. Thus, we believe this study enriches our understanding of molecular mechanisms involved with pterygium, providing insights that may contribute for the future development of new therapeutic targets for its management.

Author contributions

J.A.G. and B.W.H. wrote the main manuscript text. J.A.G., B.D., A.L.M.B. and M.G.M.V. collected data from participants and performed the experiments. J.A.G., B.W.H., L.C.B. and M.B.M. analyzed the results of the experiments and performed statistical analyses. B.W.H. prepared figures. M.A. and M.B.M. supervised the experiments and reviewed the manuscript. All authors reviewed the manuscript.

Funding

FAPESP Grant 2014/19138-5.

Competing interests

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References 1 Liu L, Wu J, Geng J, Yuan Z, Huang D. Geographical prevalence and risk factors for pterygium: A systematic review and meta-analysis. BMJ Open. 2013; 3: e003787. 24253031. 3840351 2 Shiroma H. Prevalence and risk factors of pterygium in a Southwestern Island of Japan: The Kumejima study. Am. J. Ophthalmol. 2009; 148: 766-771. 19664753 3 Artioli Schellini S, Dos Reis Veloso CE, Lopes W, Padovani CR, Pereira Padovani CR. Characteristics of patients with pterygium in the Botucatu region. Arq. Bras. Oftalmol. 2005; 68: 291-294 4 de Paula JS, Thorn F, Cruz AAV. Prevalence of pterygium and cataract in indigenous populations of the Brazilian Amazon rain forest. Eye. 2006; 20: 533-536. 1:STN:280:DC%2BD283kvVCrsQ%3D%3D. 15895023 5 Saw SM, Tan D. Pterygium: Prevalence, demography and risk factors. Ophthalmic Epidemiol. 1999; 6: 219-228. 1:STN:280:DyaK1MvhvFagsA%3D%3D. 10487976 6 Chui J. Ophthalmic pterygium. Am. J. Pathol. 2011; 178: 817-827. 21281814. 3069871 7 Wanzeler ACV. Mechanisms and biomarker candidates in pterygium development. Arq. Bras. Oftalmol. 2019; 82: 528-536. 31576927 8 Clearfield E, Muthappan V, Wang X, Kuo IC. Conjunctival autograft for pterygium. Cochrane Database Syst. Rev. 2016. 10.1002/14651858.CD011349.pub2. 26867004 9 Liang K. Expression of cell proliferation and apoptosis biomarkers in pterygia and normal conjunctiva. Mol. Vis. 2011; 17: 1687-1693. 1:CAS:528:DC%2BC3MXotFaltbs%3D. 21738398. 3130721 Koga Y. Suppression of fibrosis in human pterygium fibroblasts by butyrate and phenylbutyrate. Int. J. Ophthalmol. 2017; 10: 1337-1343. 28944189. 5596215 Siak JJK, Ng SL, Seet LF, Beuerman RW, Tong L. The nuclear-factor κB pathway is activated in pterygium. Invest. Ophthalmol. Vis. Sci. 2011; 52: 230-236. 1:CAS:528:DC%2BC3MXmsVShtrk%3D. 20811049 Chu WK, Choi HL, Bhat AK, Jhanji V. Pterygium: New insights. Eye (Basingstoke). 2020; 34: 1047-1050 Feng QY, Hu ZX, Song XL, Pan HW. Aberrant expression of genes and proteins in pterygium and their implications in the pathogenesis. Int. J. Ophthalmol. 2017; 10: 973-981. 28730091. 5515147 Ramasamy A, Mondry A, Holmes CC, Altman DG. Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Med. 2008; 5: 1320-1332. 1:CAS:528:DC%2BD1cXhtlCht7rL Tseng GC, Ghosh D, Feingold E. Comprehensive literature review and statistical considerations for microarray meta-analysis. Nucleic Acids Res. 2012; 40: 3785-3799. 1:CAS:528:DC%2BC38XmvF2mt7k%3D. 22262733. 3351145 Liu J, Ding X, Yuan L, Zhang X. Identification of pterygium-related mRNA expression profiling by microarray analysis. Eye (Basingstoke). 2017; 31: 1733-1739. 1:CAS:528:DC%2BC2sXhtVymtrzP Engelsvold DH. MiRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. Exp. Eye Res. 2013; 115: 189-198. 1:CAS:528:DC%2BC3sXhsFOltLvE. 23872359. 4278354 He S. Identification and interaction analysis of significant genes and MicroRNAs in pterygium. BioMed Res. Int. 2019. 10.1155/2019/2767512. 31976328. 6955115 Içme G. Assessment of miR-182, miR-183, miR-184, and miR-221 expressions in primary pterygium and comparison with the normal conjunctiva. Eye Contact Lens. 2019; 45: 208-211. 30688676 Han S, Chen Y, Gao Y, Sun B, Kong Y. MicroRNA-218–5p inhibit the migration and proliferation of pterygium epithelial cells by targeting EGFR via PI3K/Akt/mTOR signaling pathway. Exp. Eye Res. 2019; 178: 37-45. 1:CAS:528:DC%2BC1cXhvVejtrbP. 30243568 Chien KH. Correlation of MicroRNA-145 levels and clinical severity of pterygia. Ocul. Surf. 2013; 11: 133-138. 23583047 Cui YH. Regulation of apoptosis by miR-122 in pterygium via targeting Bcl-w. Invest. Ophthalmol. Vis. Sci. 2016; 57: 3723-3730. 1:CAS:528:DC%2BC28XhsFWktbjK. 27415790 Wu C-W. MiRNA-221 negatively regulated downstream p27Kip1 gene expression involvement in pterygium pathogenesis. Mol. Vis. 2014; 20: 1048-1056. 1:CAS:528:DC%2BC2cXhvFKgtrnJ. 25053875. 4105113 Lan W, Chen S, Tong L. MicroRNA-215 regulates fibroblast function: Insights from a human fibrotic disease. Cell Cycle. 2015; 14: 1973-1984. 1:CAS:528:DC%2BC2MXhvVKrsLfM. 25565137. 4613146 Liu J, Ding X, Yuan L, Zhang X. Identification of pterygium-related long non-coding RNAs and expression profiling by microarray analysis. Int. J. Mol. Med. 2016; 38: 529-536. 1:CAS:528:DC%2BC2sXns1emtb0%3D. 27315394 Rung J, Brazma A. Reuse of public genome-wide gene expression data. Nat. Rev. Genet. 2013; 14: 89-99. 1:CAS:528:DC%2BC38XhvV2ntLfL. 23269463 Hou Q. RankProd combined with genetic algorithm optimized artificial neural network establishes a diagnostic and prognostic prediction model that revealed C1QTNF3 as a biomarker for prostate cancer. EBioMedicine. 2018; 32: 234-244. 29861410. 6021271 Zhou G. NetworkAnalyst 3.0: A visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res. 2019. 10.1093/nar/gkz240. 31598698. 7026644 Hounkpe BW, Benatti RO, Carvalho BS, De Paula EV. Identification of common and divergent gene expression signatures in patients with venous and arterial thrombosis using data from public repositories. PLoS ONE. 2020. 10.1371/journal.pone.0235501. 32780732. 7418995 Hounkpe BW. Role of innate immunity-triggered pathways in the pathogenesis of Sickle Cell Disease: A meta-analysis of gene expression studies. Sci. Rep. 2015; 5: 17822. 2015NatSR.517822H. 1:CAS:528:DC%2BC2MXhvF2msLvN. 26648000. 4673434 Liberzon A. Molecular signatures database (MSigDB) 3.0. Bioinform. Appl. Note. 2011; 27: 1739-1740. 1:CAS:528:DC%2BC3MXntFGktLw%3D Chen EY. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 2013; 14: 128 Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. eLife. 2015; 4: e05005. 4532895 Wang B, Cunningham JM, Yang XH. Seq2pathway: An R/Bioconductor package for pathway analysis of next-generation sequencing data. Bioinformatics (Oxford, England). 2015; 31: 3043-3045. 1:CAS:528:DC%2BC28Xhs1Gisb3E Tan DT, Chee SP, Dear KB, Lim AS. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch. Ophthalmol. 1997; 115; 10: 1235-1240. 1:STN:280:DyaK2svnvVeksw%3D%3D. 9338666 Shannon P. Cytoscape: A software Environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13: 2498-2504. 1:CAS:528:DC%2BD3sXovFWrtr4%3D. 14597658. 14597658 Ritchie ME. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43: e47. 25605792. 25605792 Robin, X. et al. pROC: An open-source package for R and S+ to analyze and compare ROC curves. http://expasy.org/tools/pROC/ (2011). https://doi.org/10.1186/1471-2105-12-77. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (Oxford, England). 2003; 19: 185-193. 1:CAS:528:DC%2BD3sXitlCnsL4%3D Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. Bioinformatics. 2010; 26: 2363-2367. 1:CAS:528:DC%2BC3cXht1WhtLbJ. 20688976. 2944196 Durinck S, Spellman P, Birney E, Huber W. Mapping identifiers for the integration of genomic datasets with the R/bioconductor package biomaRt. Nat. Protoc. 2009; 4: 1184-1191. 1:CAS:528:DC%2BD1MXpt12ksrk%3D. 19617889. 3159387 Del Carratore F. RankProd 2.0: A refactored bioconductor package for detecting differentially expressed features in molecular profiling datasets. Bioinformatics (Oxford, England). 2017; 33: 2774-2775 Kolde, R. pheatmap: Pretty heatmaps. R package version 1.0.12. R package version 1.0.8 1–7 (2015). Hounkpe BW, Chenou F, De Lima F, De Paula EV. HRT Atlas v1.0 database: Redefining human and mouse housekeeping genes and candidate reference transcripts by mining massive RNA-seq datasets. Nucleic Acids Res. 2020. 10.1093/nar/gkaa609. 7778946 Bindea G. ClueGO: A cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009; 25: 1091-1093. 1:CAS:528:DC%2BD1MXksVeiu74%3D. 19237447. 19237447 Tong L. Distinct gene subsets in pterygia formation and recurrence: Dissecting complex biological phenomenon using genome wide expression data. BMC Med. Genom. 2009. 10.1186/1755-8794-2-14 Xu N, Cui Y, Dong J, Huang L. Exploring the molecular mechanisms of pterygium by constructing lncRNA–miRNA–mRNA regulatory network. Investig. Opthalmol. Vis. Sci. 2020; 61: 12. 1:CAS:528:DC%2BB3cXitVChsrvN Lafontaine PO. Trefoil factor family mRNA and protein expression in pterygium. Int. J. Oncol. 2005; 27: 997-1003. 1:CAS:528:DC%2BD2MXhtFeisr3K. 16142316 Riau AK, Wong TT, Beuerman RW, Tong L. Calcium-binding S100 protein expression in pterygium. Mol. Vis. 2009; 15: 335-342. 1:CAS:528:DC%2BD1MXis1KmsLs%3D. 19223989. 2642841 Chen Y, Wang H, Jiang Y, Zhang X, Wang Q. Transcriptional profiling to identify the key genes and pathways of pterygium. PeerJ. 2020; 8: e9056. 32411530. 7204871 Peiretti E, Dessì S, Putzolu M, Fossarello M. Hyperexpression of low-density lipoprotein receptors and hydroxy-methylglutaryl-coenzyme A-reductase in human pinguecula and primary pterygium. Invest. Ophthalmol. Vis. Sci. 2004; 45; 11: 3982-3985. 15505045 Peiretti E, Dessì S, Mulas MF, Abete C, Galantuomo MS, Fossarello M. Fibroblasts isolated from human pterygia exhibit altered lipid metabolism characteristics. Exp. Eye Res. 2006; 83; 3: 536-542. 1:CAS:528:DC%2BD28XmtVOnurk%3D. 16696971 Peiretti E, Dessì S, Mulas C, Abete C, Norfo C, Putzolu M, Fossarello M. Modulation of cholesterol homeostasis by antiproliferative drugs in human pterygium fibroblasts. Invest. Ophthalmol. Vis. Sci. 2007; 48; 8: 3450-3458. 17652712 Ozturk BT, Yıldırım MS, Zamani A, Bozkurt B. K-ras oncogene mutation in pterygium. Eye. 2017; 31; 3: 491-498. 1:CAS:528:DC%2BC28XhvVOhtrnO. 27834959 Shahraki T, Arabi A, Feizi S. Pterygium: An update on pathophysiology, clinical features, and management. Ther. Adv. Ophthalmol. 2021; 31; 13: 25158414211020152 Hung KH, Hsiao CH, Tan HY, Chen HC, Ma DH, Lin HC, Yeh LK. Clinical demographics of pterygium excision and prevalence of conjunctival intraepithelial neoplasia: A 15-year review. Int. Ophthalmol. 2020; 40; 7: 1781-1788. 32198608 Oellers P, Karp CL, Sheth A, Kao AA, Abdelaziz A, Matthews JL, Dubovy SR, Galor A. Prevalence, treatment, and outcomes of coexistent ocular surface squamous neoplasia and pterygium. Ophthalmology. 2013; 120; 3: 445-450. 23107578

By Juliana Albano de Guimarães; Bidossessi Wilfried Hounpke; Bruna Duarte; Ana Luiza Mylla Boso; Marina Gonçalves Monteiro Viturino; Letícia de Carvalho Baptista; Mônica Barbosa de Melo and Monica Alves

Reported by Author; Author; Author; Author; Author; Author; Author; Author

Titel:
Transcriptomics and network analysis highlight potential pathways in the pathogenesis of pterygium.
Autor/in / Beteiligte Person: de Guimarães JA ; Hounpke, BW ; Duarte, B ; Boso, ALM ; Viturino, MGM ; de Carvalho Baptista L ; de Melo MB ; Alves, M
Link:
Zeitschrift: Scientific reports, Jg. 12 (2022-01-07), Heft 1, S. 286
Veröffentlichung: London : Nature Publishing Group, copyright 2011-, 2022
Medientyp: academicJournal
ISSN: 2045-2322 (electronic)
DOI: 10.1038/s41598-021-04248-x
Schlagwort:
  • Adult
  • Aged
  • Databases, Genetic
  • Female
  • Gene Expression Regulation
  • Humans
  • Male
  • Middle Aged
  • Oligonucleotide Array Sequence Analysis
  • Pterygium physiopathology
  • Pterygium surgery
  • Gene Expression Profiling
  • Gene Regulatory Networks
  • MicroRNAs genetics
  • Pterygium genetics
  • RNA, Messenger genetics
  • Transcriptome
Sonstiges:
  • Nachgewiesen in: MEDLINE
  • Sprachen: English
  • Publication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • Language: English
  • [Sci Rep] 2022 Jan 07; Vol. 12 (1), pp. 286. <i>Date of Electronic Publication: </i>2022 Jan 07.
  • MeSH Terms: Gene Expression Profiling* ; Gene Regulatory Networks* ; Transcriptome* ; MicroRNAs / *genetics ; Pterygium / *genetics ; RNA, Messenger / *genetics ; Adult ; Aged ; Databases, Genetic ; Female ; Gene Expression Regulation ; Humans ; Male ; Middle Aged ; Oligonucleotide Array Sequence Analysis ; Pterygium / physiopathology ; Pterygium / surgery
  • References: Bioinformatics. 2009 Apr 15;25(8):1091-3. (PMID: 19237447) ; Am J Pathol. 2011 Feb;178(2):817-27. (PMID: 21281814) ; Ther Adv Ophthalmol. 2021 May 31;13:25158414211020152. (PMID: 34104871) ; Biomed Res Int. 2019 Jun 25;2019:2767512. (PMID: 31341891) ; PLoS Med. 2008 Sep 30;5(9):e184. (PMID: 18767902) ; Sci Rep. 2015 Dec 09;5:17822. (PMID: 26648000) ; Ophthalmology. 2013 Mar;120(3):445-450. (PMID: 23107578) ; BMC Med Genomics. 2009 Mar 10;2:14. (PMID: 19272163) ; Nucleic Acids Res. 2019 Jul 2;47(W1):W234-W241. (PMID: 30931480) ; Bioinformatics. 2003 Jan 22;19(2):185-93. (PMID: 12538238) ; Mol Vis. 2014 Jul 21;20:1048-56. (PMID: 25053875) ; Bioinformatics. 2015 Sep 15;31(18):3043-5. (PMID: 25979472) ; Elife. 2015 Aug 12;4:. (PMID: 26267216) ; EBioMedicine. 2018 Jun;32:234-244. (PMID: 29861410) ; PeerJ. 2020 May 04;8:e9056. (PMID: 32411530) ; Nat Rev Genet. 2013 Feb;14(2):89-99. (PMID: 23269463) ; Eye Contact Lens. 2019 May;45(3):208-211. (PMID: 30688676) ; Nat Protoc. 2009;4(8):1184-91. (PMID: 19617889) ; Nucleic Acids Res. 2012 May;40(9):3785-99. (PMID: 22262733) ; Arq Bras Oftalmol. 2005 May-Jun;68(3):291-4. (PMID: 16059556) ; Int J Mol Med. 2016 Aug;38(2):529-36. (PMID: 27315394) ; BMC Bioinformatics. 2013 Apr 15;14:128. (PMID: 23586463) ; Eye (Lond). 2020 Jun;34(6):1047-1050. (PMID: 32029918) ; Invest Ophthalmol Vis Sci. 2004 Nov;45(11):3982-5. (PMID: 15505045) ; Exp Eye Res. 2019 Jan;178:37-45. (PMID: 30243568) ; Exp Eye Res. 2006 Sep;83(3):536-42. (PMID: 16696971) ; Bioinformatics. 2011 Jun 15;27(12):1739-40. (PMID: 21546393) ; Exp Eye Res. 2013 Oct;115:189-98. (PMID: 23872359) ; Bioinformatics. 2017 Sep 01;33(17):2774-2775. (PMID: 28481966) ; Eye (Lond). 2006 May;20(5):533-6. (PMID: 15895023) ; Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3450-8. (PMID: 17652712) ; Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792) ; Eye (Lond). 2017 Dec;31(12):1733-1739. (PMID: 28664906) ; Int Ophthalmol. 2020 Jul;40(7):1781-1788. (PMID: 32198608) ; Am J Ophthalmol. 2009 Nov;148(5):766-771.e1. (PMID: 19664753) ; Mol Vis. 2011;17:1687-93. (PMID: 21738398) ; PLoS One. 2020 Aug 11;15(8):e0235501. (PMID: 32780732) ; Ocul Surf. 2013 Apr;11(2):133-8. (PMID: 23583047) ; Nucleic Acids Res. 2021 Jan 8;49(D1):D947-D955. (PMID: 32663312) ; Cell Cycle. 2015;14(12):1973-84. (PMID: 25565137) ; Bioinformatics. 2010 Oct 1;26(19):2363-7. (PMID: 20688976) ; Arch Ophthalmol. 1997 Oct;115(10):1235-40. (PMID: 9338666) ; BMJ Open. 2013 Nov 19;3(11):e003787. (PMID: 24253031) ; Genome Res. 2003 Nov;13(11):2498-504. (PMID: 14597658) ; Int J Ophthalmol. 2017 Sep 18;10(9):1337-1343. (PMID: 28944189) ; BMC Bioinformatics. 2011 Mar 17;12:77. (PMID: 21414208) ; Ophthalmic Epidemiol. 1999 Sep;6(3):219-28. (PMID: 10487976) ; Arq Bras Oftalmol. 2019 Sep 30;82(6):528-536. (PMID: 31576927) ; Eye (Lond). 2017 Mar;31(3):491-498. (PMID: 27834959) ; Int J Ophthalmol. 2017 Jun 18;10(6):973-981. (PMID: 28730091) ; Invest Ophthalmol Vis Sci. 2016 Jul 1;57(8):3723-30. (PMID: 27415790) ; Mol Vis. 2009;15:335-42. (PMID: 19223989) ; Invest Ophthalmol Vis Sci. 2020 Jul 1;61(8):12. (PMID: 32645133) ; Int J Oncol. 2005 Oct;27(4):997-1003. (PMID: 16142316) ; Cochrane Database Syst Rev. 2016 Feb 11;2:CD011349. (PMID: 26867004) ; Invest Ophthalmol Vis Sci. 2011 Jan 05;52(1):230-6. (PMID: 20811049)
  • Grant Information: 2014/19138-5 Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Substance Nomenclature: 0 (MicroRNAs) ; 0 (RNA, Messenger)
  • Entry Date(s): Date Created: 20220108 Date Completed: 20220224 Latest Revision: 20240405
  • Update Code: 20240405
  • PubMed Central ID: PMC8741985

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -